Mexico · Delayed Price · Currency is MXN Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of MXN 3.18 trillion. The enterprise value is 3.40 trillion.
| Market Cap | 3.18T |
| Enterprise Value | 3.40T |
Important Dates
The last earnings date was Tuesday, February 10, 2026.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | Dec 15, 2025 |
Share Statistics
| Current Share Class | 1.24B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 89.29% |
| Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 20.77 and the forward PE ratio is 16.89.
| PE Ratio | 20.77 |
| Forward PE | 16.89 |
| PS Ratio | 6.00 |
| PB Ratio | 7.81 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.69 |
| P/OCF Ratio | 17.64 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.41, with an EV/FCF ratio of 19.99.
| EV / Earnings | 22.21 |
| EV / Sales | 6.72 |
| EV / EBITDA | 13.41 |
| EV / EBIT | 16.74 |
| EV / FCF | 19.99 |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.
| Current Ratio | 1.55 |
| Quick Ratio | 1.23 |
| Debt / Equity | 1.13 |
| Debt / EBITDA | 1.73 |
| Debt / FCF | 2.70 |
| Interest Coverage | 11.54 |
Financial Efficiency
Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.
| Return on Equity (ROE) | 40.66% |
| Return on Assets (ROA) | 12.52% |
| Return on Invested Capital (ROIC) | 26.86% |
| Return on Capital Employed (ROCE) | 25.03% |
| Weighted Average Cost of Capital (WACC) | 6.01% |
| Revenue Per Employee | 31.18M |
| Profits Per Employee | 9.01M |
| Employee Count | 17,000 |
| Asset Turnover | 0.50 |
| Inventory Turnover | 3.58 |
Taxes
In the past 12 months, Gilead Sciences has paid 23.15 billion in taxes.
| Income Tax | 23.15B |
| Effective Tax Rate | 13.13% |
Stock Price Statistics
The stock price has increased by +7.79% in the last 52 weeks. The beta is 0.39, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | +7.79% |
| 50-Day Moving Average | 2,254.01 |
| 200-Day Moving Average | 1,802.60 |
| Relative Strength Index (RSI) | 58.93 |
| Average Volume (20 Days) | 1,765 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.95 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of MXN 530.07 billion and earned 153.21 billion in profits. Earnings per share was 122.06.
| Revenue | 530.07B |
| Gross Profit | 417.91B |
| Operating Income | 212.74B |
| Pretax Income | 176.36B |
| Net Income | 153.21B |
| EBITDA | 262.43B |
| EBIT | 212.74B |
| Earnings Per Share (EPS) | 122.06 |
Balance Sheet
The company has 173.06 billion in cash and 459.82 billion in debt, with a net cash position of -233.21 billion.
| Cash & Cash Equivalents | 173.06B |
| Total Debt | 459.82B |
| Net Cash | -233.21B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 407.20B |
| Book Value Per Share | 329.34 |
| Working Capital | 117.54B |
Cash Flow
In the last 12 months, operating cash flow was 180.37 billion and capital expenditures -10.14 billion, giving a free cash flow of 170.24 billion.
| Operating Cash Flow | 180.37B |
| Capital Expenditures | -10.14B |
| Free Cash Flow | 170.24B |
| FCF Per Share | n/a |
Margins
Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.
| Gross Margin | 78.84% |
| Operating Margin | 40.14% |
| Pretax Margin | 33.27% |
| Profit Margin | 28.90% |
| EBITDA Margin | 49.51% |
| EBIT Margin | 40.14% |
| FCF Margin | 32.12% |
Dividends & Yields
This stock pays an annual dividend of 59.68, which amounts to a dividend yield of 2.42%.
| Dividend Per Share | 59.68 |
| Dividend Yield | 2.42% |
| Dividend Growth (YoY) | 3.21% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 48.89% |
| Buyback Yield | 0.24% |
| Shareholder Yield | 2.66% |
| Earnings Yield | 4.82% |
| FCF Yield | 5.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.9 |
| Piotroski F-Score | 7 |